CDH1 Loss

CI-VAR-00002512Explore in graph →CIViC 5379

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
CDH1 Loss	Crizotinib + ForetinibSubstitutes	Predictive	D	Supports Sensitivity Response	2	submitted	EID12768 In preclinical breast cancer models, including CRISPR-engineered E-cadherin-deficient MCF7 and MCF10A isogenic pairs, a 34-breast-cell-line siRNA and drug-screen panel, ex vivo breast cancer explants,… (full text at CIViC) PMID 29610289 · Bajrami et al., 2018 · Open in CIViC	civic
Unmapped disease2unmapped disease
CDH1 Loss	(functional)	Functional	D	Supports Loss Of Function	2	submitted	EID12746 In functional preclinical models, CDH1 loss was associated with activation of ECM–DDR2–AKT signaling and increased sensitivity to kinase inhibition. Reactome analysis of AKT3-associated genes in CDH1-…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.